ESR1 and breast cancer: However, 5αP and 3αHP are reported to act with equal efficacy regardless of the receptor status of the breast cancer cell line evaluated.20 Therefore, additional research to assess circulating associations by tumor characteristics (eg, ER/PR/ERBB2 [previously HER2] status) appears to be warranted.